Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Thrombophilia D019851 6 associated lipids
Endotoxemia D019446 27 associated lipids
Pancreatitis, Acute Necrotizing D019283 18 associated lipids
Atrial Premature Complexes D018880 1 associated lipids
Sepsis D018805 11 associated lipids
Systemic Inflammatory Response Syndrome D018746 4 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Osteoblastoma D018215 1 associated lipids
Aortic Aneurysm, Abdominal D017544 5 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Armstrong PC et al. Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. 2010 J. Thromb. Haemost. pmid:19995405
Carroll RC et al. Post interventional cardiology urinary thromboxane correlates with PlateletMapping detected aspirin resistance. 2010 Thromb. Res. pmid:19962724
Dragani A et al. Clinical and laboratory phenotype associated with the aspirin-like defect. 2010 Br. J. Haematol. pmid:19814736
Maddens BE et al. Validation of immunoassays for the candidate renal markers C-reactive protein, immunoglobulin G, thromboxane B2 and retinol binding protein in canine urine. 2010 Vet. Immunol. Immunopathol. pmid:19815297
Parmar JH et al. Significant prostacyclin/thromboxane level imbalance after lower limb arterial angioplasty: a possible platelet function alteration. 2010 J Vasc Interv Radiol pmid:20800778
Kawabata K et al. Inhibition of secretory phospholipase A2 activity attenuates acute cardiogenic pulmonary edema induced by isoproterenol infusion in mice after myocardial infarction. 2010 J. Cardiovasc. Pharmacol. pmid:20625313
De la Cruz JP et al. Differences in the in vitro antiplatelet effect of dexibuprofen, ibuprofen, and flurbiprofen in human blood. 2010 Anesth. Analg. pmid:21048099
Renda G et al. Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance. 2010 Haematologica pmid:21123440
Iagoda AV and Gladkikh NN [Thromboxane-prostacyclin balance and platelet aggregability in patients with minor cardiac abnormalities]. 2010 Ter. Arkh. pmid:21086621
Fukushima H et al. Mechanisms underlying early development of pulmonary vascular obstructive disease in Down syndrome: An imbalance in biosynthesis of thromboxane A2 and prostacyclin. 2010 Am. J. Med. Genet. A pmid:20583254
Huang HC et al. Simvastatin effects on portal-systemic collaterals of portal hypertensive rats. 2010 J. Gastroenterol. Hepatol. pmid:20659230
Ferrante E et al. Determinants of thromboxane biosynthesis in rheumatoid arthritis: Role of RAGE and oxidant stress. 2010 Free Radic. Biol. Med. pmid:20541603
Antonino MJ et al. Antiplatelet effects of aspirin with phytosterols: comparison with non-enteric coated aspirin alone. 2010 Thromb. Res. pmid:19446864
Iwasaki W et al. Changes in the fatty acid composition of the liver with the administration of N-3 polyunsaturated fatty acids and the effects on warm ischemia/reperfusion injury in the rat liver. 2010 Shock pmid:19543146
Dołegowska B et al. Dynamics of thromboxane level changes during early phase of allograft reperfusion. 2009 Sep-Oct Clin Transplant pmid:19298388
Tantry US et al. Aspirin resistance. 2009 Sep-Oct Prog Cardiovasc Dis pmid:19732606
Thomson VS et al. Aspirin resistance in Indian patients with coronary artery disease and cardiovascular events. 2009 Oct-Dec J Postgrad Med pmid:20083870
Goodman L et al. Effects of firocoxib and tepoxalin on healing in a canine gastric mucosal injury model. 2009 Jan-Feb J. Vet. Intern. Med. pmid:19175721
Guerrero MD et al. Anti-inflammatory and analgesic activity of a novel inhibitor of microsomal prostaglandin E synthase-1 expression. 2009 Eur. J. Pharmacol. pmid:19686718
Dietrich-Muszalska A and Olas B Isoprostenes as indicators of oxidative stress in schizophrenia. 2009 World J. Biol. Psychiatry pmid:19673085
Lowe FJ et al. Evaluation of biomarkers of exposure and potential harm in smokers, former smokers and never-smokers. 2009 Clin. Chem. Lab. Med. pmid:19676143
Stanke-Labesque F et al. Increased urinary leukotriene E4 excretion in obstructive sleep apnea: effects of obesity and hypoxia. 2009 J. Allergy Clin. Immunol. pmid:19596146
Coates AM et al. Regular consumption of n-3 fatty acid-enriched pork modifies cardiovascular risk factors. 2009 Br. J. Nutr. pmid:18590592
Huntjens DR et al. Differences in the sensitivity of behavioural measures of pain to the selectivity of cyclo-oxygenase inhibitors. 2009 Eur J Pain pmid:18774319
Correa JA et al. Virgin olive oil polyphenol hydroxytyrosol acetate inhibits in vitro platelet aggregation in human whole blood: comparison with hydroxytyrosol and acetylsalicylic acid. 2009 Br. J. Nutr. pmid:18775097
Hynninen VV et al. Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib. 2009 Eur. J. Clin. Pharmacol. pmid:18777173
Muir AR et al. Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. 2009 Heart pmid:18697805
Foudi N et al. Selective cyclooxygenase-2 inhibition directly increases human vascular reactivity to norepinephrine during acute inflammation. 2009 Cardiovasc. Res. pmid:18952694
Rogers LK et al. Differential responses in the lungs of newborn mouse pups exposed to 85% or >95% oxygen. 2009 Pediatr. Res. pmid:18703992
Fernández-Arche A et al. Long-chain fatty alcohols from pomace olive oil modulate the release of proinflammatory mediators. 2009 J. Nutr. Biochem. pmid:18555679
Kanazawa S et al. Effect of low-dose aspirin for skin rash associated with erlotinib therapy in patients with lung cancer. 2009 Platelets pmid:19172526
Calapai G et al. Cardiovascular biomarkers in groups of established smokers after a decade of smoking. 2009 Basic Clin. Pharmacol. Toxicol. pmid:19175368
Kapetanovic IM et al. Comparison of pharmacokinetic and pharmacodynamic profiles of aspirin following oral gavage and diet dosing in rats. 2009 Chem. Biol. Interact. pmid:18992230
Seta F et al. Renal and cardiovascular characterization of COX-2 knockdown mice. 2009 Am. J. Physiol. Regul. Integr. Comp. Physiol. pmid:19357295
Pettinella C et al. Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin. 2009 Thromb. Haemost. pmid:19350112
Guagnano MT et al. Determinants of platelet activation in hypertensives with microalbuminuria. 2009 Free Radic. Biol. Med. pmid:19280705
Lo HM et al. 2'-Ethoxy-5'-methoxy-2-(5-methylthienyl)chalcone inhibits collagen-induced protein tyrosine phosphorylation and thromboxane formation during platelet aggregation and adhesion. 2009 Pharmacology pmid:19690443
Struthmann L et al. Prothrombotic effects of diclofenac on arteriolar platelet activation and thrombosis in vivo. 2009 J. Thromb. Haemost. pmid:19691487
Omura Y et al. Severe asthma with markedly increased asbestos of 2 types & TXB2, and markedly reduced acetylcholine, DHEA & drug uptake in parts of upper lungs, & similar abnormalities at respiratory & cardiac center of medulla oblongata: complete elimination of this asthma within 15 days using one optimal dose of astragalus & application of strong red light & EMF neutralizer on respiratory centers of abnormal medulla oblongata. 2009 Acupunct Electrother Res pmid:19711774
Sobotková A et al. Antioxidants change platelet responses to various stimulating events. 2009 Free Radic. Biol. Med. pmid:19766712
Lauring B et al. Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects. 2009 J Clin Pharmacol pmid:19833861
Cattaneo M Letter by cattaneo regarding article, "incomplete inhibition of thromboxane biosynthesis by acetylsalicylic Acid: determinants and effect on cardiovascular risk". 2009 Circulation pmid:19546394
Schiff M et al. Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin. 2009 Curr Med Res Opin pmid:19678751
Cook VL et al. Effect of firocoxib or flunixin meglumine on recovery of ischemic-injured equine jejunum. 2009 Am. J. Vet. Res. pmid:19645580
Blais N et al. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). 2009 Thromb. Haemost. pmid:19652893
Zhang X et al. Effect of baicalin on inflammatory mediator levels and microcirculation disturbance in rats with severe acute pancreatitis. 2009 Pancreas pmid:19657312
Liu FC et al. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase. 2009 Biochem. Pharmacol. pmid:19426675
Li L et al. The anti-inflammatory effects of ZLJ-6, a novel dual cyclooxygenase/5-lipoxygenase inhibitor. 2009 Eur. J. Pharmacol. pmid:19243697
Peng CY et al. Dietary soy protein selectively reduces renal prostanoids and cyclooxygenases in polycystic kidney disease. 2009 Exp. Biol. Med. (Maywood) pmid:19429858
Li H et al. [Effect of an integrative medical regimen on levels of vascular endothelial function and hypersensitive C-reactive protein in elderly patients with isolated systolic hypertension]. 2009 Zhongguo Zhong Xi Yi Jie He Za Zhi pmid:19382469